$MRNA (-7,24%)

During the COVID-19 pandemic, Moderna's share price shot to a peak of $497.49 in August 2021, driven by the rapid development of its mRNA vaccine Spikevax. The company posted revenue of $18.5 billion in 2021, almost entirely from vaccine sales, unprecedented growth for a biotech company with no previous commercial successes. Moderna benefited from global demand for vaccines, government contracts and unparalleled optimism about mRNA technology, making it a darling of investors. By comparison, Pfizer, with its broader portfolio and vaccine Comirnaty (along with BioNTech), also saw huge gains, with more than $80 billion in vaccine sales, but maintained stability through its diversified earnings.[](https://www.fool.com/investing/2025/03/15/down-93-is-it-finally-time-to-buy-moderna/)[](https://www.fool.com/investing/2025/03/15/down-93-is-it-finally-time-to-buy-moderna/)[](https://www.statnews.com/2024/03/25/covid-vaccine-financial-winners-losers-pfizer-biontech-moderna-astrazeneca/)

Now, on Aug. 1, 2025, Moderna's stock has plummeted to $27.20, down more than 94% from its peak. This free fall reflects a stark reality: demand for COVID-19 vaccines collapsed as the pandemic moved into an endemic phase. Moderna's 2024 sales plummeted 53% to $3.2 billion, with a net loss per share of $9.28. Recent quarterly results (Q2 2025) show a further decline to $128.3 million, 46.8% below expectations, exacerbated by the cancellation of a $766 million government contract and the withdrawal of an FDA application for a flu-COVID combination vaccine.[](https://www.fool.com/investing/2025/03/15/down-93-is-it-finally-time-to-buy-moderna/)[](https://www.fool.com/investing/2025/04/03/better-beaten-down-stock-to-buy-pfizer-vs-moderna/)[](https://www.tradingview.com/symbols/NASDAQ-MRNA/)

Moderna's reliance on Spikevax is an Achilles heel. While Pfizer spreads its revenues across oncology, immunology and RSV vaccines such as Abrysvo, Moderna's pipeline remains speculative. Despite promises of RSV and cancer vaccines such as mRESVIA and a collaboration with Merck for Keytruda, approvals and revenues remain uncertain. Recent staff reductions of 10% and planned cost cuts of $1.4-1.7 billion by 2027 underscore financial stress.[](https://www.fool.com/investing/2025/04/03/better-beaten-down-stock-to-buy-pfizer-vs-moderna/)[](https://www.fool.com/investing/2025/04/03/better-beaten-down-stock-to-buy-pfizer-vs-moderna/)[](https://www.investing.com/news/swot-analysis/modernas-swot-analysis-mrna-stock-faces-challenges-amid-vaccine-shifts-93CH-4095957)

With a market capitalization of $12.7 billion and negative earnings per share of -$8.72, Moderna is struggling to regain investor confidence. Analysts forecast a $46.76 price target, but pessimism prevails due to competition from Pfizer and BioNTech, pricing pressure and an oversaturated vaccine market. Moderna's glory days appear to be over; without breakthroughs in its pipeline, further stagnation looms, while Pfizer is better positioned for a post-COVID world.[](https://nl.investing.com/equities/moderna)[](https://stockanalysis.com/stocks/mrna/)

Today I'm going to show you my best and worst trades since the start of my investment journey. No show, no excuses - just real numbers and learnings.

🟢 My top 15 trades

📈 From Rheinmetall to Palantir to Ferrari - some positions really took off.

Biggest single gain: +131 % for Rheinmetall💪

→ The majority came from strategically placed opportunities, not luck.

🔴 My flop 15 trades

📉 Nvidia put, Mainz Biomed, BrainChip... The biggest flop?

-99.76 % with a warrant on Nvidia 😬

→ The lesson: highly speculative bets quickly go against you - especially without a plan.

📘 My most important learning

I learned this lesson in my first year of investing:

Short-term trading may work from time to time - but not in the long term.

Today I have a clear strategy:

✅ Core-satellite

✅ Focus on quality

✅ Discipline & long-termism

🧠 Why am I sharing this?

Transparency is not a buzzword for me - it's a duty.

Losses are part of it. If you only talk about your profits, you're only telling half the truth.

#Trading
#Fehler
#Investieren
#Transparenz
#Learnings
#DepotEinblick
#DerSpekulant
#Getquin

$RHM (+0,57%)
$NVDA (+0,32%)
$MC (+0,59%)
$MYNZ
$BRN (+0,09%)
$COIN (+0,07%)
$RACE (-0,29%)
$TSLA (+7,29%)
$WDL1 (-1,19%)
$PLTR (+4,15%)
$PTON (-1,22%)
$9866 (+2,15%)
$MULN
$MRNA (-7,24%)
$VBK (-0,35%)
$JKS (+4,53%)
$TPE (-1,23%)
$PFIZER
$SLI (+1,63%)

⚠Only for those interested in trading - otherwise keep scrolling 😅

@MCKrummel-Divi-Holding Since I'm sitting at the computer after your comment, here are a few examples -> this is what the screener "spit out"

@Epi the recently discussed setup, I always look at the same pattern. Well secured on the downside

@Dividenden_Monteur something for you?😎

PS: I have added the link to the chart pictures everywhere, so you can still follow the chart live until the close of trading if you are interested 👈

$MRNA (-7,24%)
https://www.tradingview.com/x/vzNaFp6T/

$HOOD (-1,9%) wait here how it develops on the VWAP https://www.tradingview.com/x/l4g6iRhL/

$VRNT (-0,29%)
https://www.tradingview.com/x/usbMLEAZ/

$NXT
https://www.tradingview.com/x/hzo2u5SA/

$FSLR (-0,7%)
https://www.tradingview.com/x/JWZVSjVl/

$W (-2,21%)
https://www.tradingview.com/x/rCO7KhVs/

@Multibagger my tubular cracker $STZ (-2,34%) maybe something will happen, from the -8% we are already at only -3% - I'll give this swing trade a little more time 🤕

#trading
#daytrading

$BNTX (-5,06%) has taken quite a beating in pre-market trading today. R.F. Kennedy and Peter Marks (FDA) have parted ways following differences of opinion on the subject of vaccinations. The vaccine values such as $BNTX (-5,06%) and $MRNA (-7,24%) have suffered. For me, this is a good opportunity to add to my BionTech position right after the US IPO - I am speculating on a breakthrough in the oncology pipeline in 2026. Biontech is one of my long term swings.

In addition to Biontech, I also added to my $RDC (+1,91%) Shopapotheke position again today.

Moderna in crisis

The Moderna share comes under pressure on Thursday. Moderna $MRNA (-7,24%)-shares fell 4.14 percent at one point after reports surfaced that the U.S. Department of Health and Human Services is re-evaluating the $590 million contract to develop an avian flu vaccine. The contract, awarded to Moderna in the final days of the Biden administration, was intended to accelerate mRNA-based vaccines in the event of an avian flu pandemic. Investors are concerned about whether the contract is in jeopardy and what impact this could have on Moderna's future.

Snowflake surprises with strong figures

The AI company Snowflake $SNOW (-2,18%) had a successful fourth quarter thanks to strong demand for AI. The figures exceeded analysts' expectations at all levels. Turnover amounted to 986.8 million US dollars, while analysts had only expected 956.9 million US dollars. The result was also surprising: earnings amounted to 30 cents per share, which was better than the 18 cents that had been expected. CEO Sridhar Ramaswamy emphasized that Snowflake is considered the most important data and AI company in the world and sees enormous growth potential. The share price reacted with a jump of 7.35 percent to 178.40 US dollars.

MTU Aero Engines: Insider buys shares

The MTU Aero Engines $MTX (-0,4%)-share, there is news from the insider sector. On February 25, 2025, CEO Maurer, Dr. Silke, acquired 42 shares at EUR 306.90 each. On BaFin's publication date, the share price rose by 1 percent to EUR 321.60. A total of 923 MTU shares changed hands in FSE trading. Dr. Maurer had already increased his position by 95 shares at EUR 305.70 on the same day. MTU Aero Engines has a market capitalization of EUR 17.16 billion, which underlines the executive's interest in his own share.

Sources:

https://www.finanzen.net/nachricht/aktien/risiko-fuer-anleger-moderna-aktie-stuerzt-ab-millionenvertrag-um-vogelgrippe-impfstoff-in-gefahr-14277323

https://www.finanzen.net/nachricht/aktien/erwartungen-uebertroffen-snowflake-aktie-mit-kurssprung-snowflake-meldet-ueberraschend-starke-quartalszahlen-14275993

https://www.finanzen.net/nachricht/aktien/mtu-aero-engines-aktie-fuehrungskraft-investiert-in-eigene-anteile-14279859

Last year was a complete success for many investors - but not for everyone. While the S&P 500 rose by around 25 %, there were also shares that took a nosedive. 🤔

The biggest losers included companies such as Celanese Corp. $CE (-2,75%), which fell by 19.25 %, and Estée Lauder ($EL (-4,03%)which lost 1.45 %. Intel $INTC (-2,38%) and Moderna $MRNA (-7,24%) were also under pressure.

But what does that mean? Are yesterday's flops the potential stars of tomorrow? Some analysts see recovery potential, while others point to the ongoing challenges.

What do you think? Is it worth buying into these supposed bargains now, or is staying away the better strategy? Let's discuss it! 📈💬